Seer Q2 Revenue Plunges 23% as Funding Headwinds Bite
SEER sits 40% above its 52-week low of $1.55 on light trading volume (0.2× avg).
Summary
Seer's Q2 revenue dropped 23% year-over-year to $3.10 million, driven by macroeconomic pressures on academic and government funding. The net loss narrowed to $16.9 million, helped by a 19% cut in operating expenses. Management maintained full-year revenue guidance of $16–$18 million, signaling confidence in a second-half recovery. This comes amid an ongoing proxy battle and multiple unsolicited acquisition bids, with the stock trading at $2.17—well below the latest $2.45 per share offer from the CEO. The results underscore the company's struggle to grow while activist pressure mounts.
At the time of this announcement, SEER was trading at $2.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $119.5M. The 52-week trading range was $1.55 to $2.41. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.